These drugs have a high affinity for PPARγ, which is an attractive pharmacological target for treating T2DM since it simultaneously modulates several of the pathways disrupted in T2DM and metabolic syndrome by enhancing the expression of genes involved in glucose and lipid metabolism and increasing the expression of glucose transporter type 4 (GLUT4), an insulin-stimulated glucose transport system expressed in muscle cells and the expression of GLUT4 is highly regulated by PPARγ (2, 26, 27). The gene discussed is PPARG; the disease is metabolic syndrome.